FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology and can be used for treating neovascular age-related macular degeneration. That is ensured by the intravitreal introduction of the neoangiogenesis inhibitor brolucizumab in dose of 6 mg. Betamethasone 0.5 ml is introduced into the sub-Tenon space. Preparations are administered three times every 4 weeks; the therapeutic course is 12 weeks.
EFFECT: invention provides effective treatment of the given pathology, stable improvement of visual acuity, reduced risk of side effects with reduced frequency of intraocular injections.
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF MACULAR EDEMA OF RETINA | 2016 |
|
RU2635530C1 |
| METHOD FOR COMBINED TREATMENT OF MACULAR OEDEMA OF RETINA | 2015 |
|
RU2622031C1 |
| METHOD FOR TREATMENT OF CATARACT IN PATIENTS WITH ACTIVE NEOVASCULAR DISEASES OF MACULA | 2017 |
|
RU2659144C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF MYOPIC CHOROIDAL NEOVASCULARIZATION AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN MYOPIC EYES | 2020 |
|
RU2749120C1 |
| COMBINED METHOD FOR TREATING CHOROIDAL NEOVASCULATION OF ALL TYPES | 2021 |
|
RU2770745C1 |
| METHOD OF TREATMENT OF CHOROIDAL NEOVASCULATION | 2018 |
|
RU2676075C1 |
| METHOD OF TREATING EYE DISEASES | 2015 |
|
RU2722643C2 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
| METHOD FOR TREATMENT OF EYE DISEASES | 2015 |
|
RU2771900C2 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF SUBRETINAL FIBROSIS IN PATIENTS WITH EXUDATIVE FORM OF AGE-RELATED MACULAR DEGENERATION GIVEN ANTI-VEGF THERAPY | 2022 |
|
RU2793419C1 |
